Registering Genomics and Imaging of Tumors (ReGIT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-18

Study Completion Date

2032-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Eloquent Function in Brain Tumor Patients

NCT01535430

Primary Brain Tumor Metastatic Brain Tumor

RECRUITING

Spectroscopic Magnetic Resonance Imaging of Glioma

NCT03677999

Brain Tumor-Glioma

WITHDRAWN

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

NCT05559853

Brain Metastases Brain Metastases, Adult Metastatic Brain Tumor +1 more

RECRUITING

Non-invasive Glioma Characterization Through Molecular Imaging

NCT03684109

Glioma Brain Tumor Primary Brain Tumor +2 more

RECRUITING NA

Development and Validation of Advanced MRI Methods for Clinical Applications

NCT03264300

Brain Tumor

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations. Subjects who are radiologically diagnosed with gliomas and are expected to undergo a tumor biopsy will be enrolled in the study. Subjects will complete two visits and will then undergo a follow-up period. At the baseline visit, subjects will under go a pregnancy test (if applicable), two PET-CT scans using different radioactive tracers, an MRI scan, and blood draws. At the biopsy visit, the subject will undergo an MRI scan as part of their standard of care and at least biopsy samples will be collected for research purposes using stereotactic core biopsy. The study team will take pictures of the locations of tumor samples as they are removed during surgery. The samples then get studied for genetic mutations, and the study team will look at the parts of the image the samples came from to see if they could have been predicted. Follow-up MRIs and potentially other radiology scans will be completed as part of subjects' regular care on a schedule determined by their healthcare provider at the facility ordered by their physician. The study team will follow subjects' care and collect the information from their regularly scheduled treatments and brain scans after their biopsy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baseline Imaging and Biopsy

Subjects will receive a PET-CT with the radiopharmaceuticals FET and O-15 Water (under RDRC approval for basic research) prior to their standard of care neurosurgery via stereotactic core biopsy. Research samples will be collected for analysis intraoperatively.

FET F-18

Intervention Type DRUG

PET scan with FET prior to biopsy

O-15 Radioisotope

Intervention Type DRUG

PET scan with O-15 Water prior to biopsy

CT scan

Intervention Type PROCEDURE

CT scan prior to biopsy

MRI with gadolinium-based contrast

Intervention Type PROCEDURE

MRI prior to biopsy

Biopsy Collection

Intervention Type PROCEDURE

Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FET F-18

PET scan with FET prior to biopsy

Intervention Type DRUG

O-15 Radioisotope

PET scan with O-15 Water prior to biopsy

Intervention Type DRUG

CT scan

CT scan prior to biopsy

Intervention Type PROCEDURE

MRI with gadolinium-based contrast

MRI prior to biopsy

Intervention Type PROCEDURE

Biopsy Collection

Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

O-15 Water

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is between 18 and 89 years of age.
2. Subject has radiologically-diagnosed or suspected WHO Grade II-IV glioma based on physician review or conformance with published WHO criteria as evaluated by the PI\*.
3. Subject is treatment-naïve with the exception of previous biopsy for the above condition.
4. Subject is planning to undergo surgical resection and biopsy of their brain tumor.
5. Subject has sufficient tissue so that the study team is able to acquire at least 2 biopsy samples during resection.
6. Subject is able to read and write in English.
7. Subject is able to lay supine for up to 80 minutes.
8. Subject is able to hold still during MRI procedures.
9. Subject or their LAR has signed the consent form for participation in the study.

Exclusion Criteria

1. Subject has conditions that would preclude the completion of an MRI such as claustrophobia, pacemaker, metal objects in the body, and/or pregnancy.
2. Subject has serious unstable medical or mental illness.
3. Subject has insufficient tissue to acquire at least two biopsy samples during resection.
4. Subject has a medical contraindication to any element of the study procedures.
5. Subject or their LAR has not read and signed the informed consent form, or does not understand its contents.
6. Subject is pregnant.\*\*
7. Subject is at high risk for NSF (eGFR\<60 or serum creatine \>1.3) and cannot follow the weight-based dosing protocol for Gadavist.\*\*\*

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No